Seres Therapeutics (NASDAQ:MCRB) PT Lowered to $4.00 at Oppenheimer

Seres Therapeutics (NASDAQ:MCRB) had its price target lowered by analysts at Oppenheimer from $5.00 to $4.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective points to a potential upside of 308.71% from the stock’s current price.

Separately, Chardan Capital reduced their target price on shares of Seres Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday.

Seres Therapeutics Stock Performance

NASDAQ MCRB traded up $0.23 during trading hours on Thursday, hitting $0.98. The company had a trading volume of 13,837,503 shares, compared to its average volume of 5,036,132. The business has a 50 day moving average of $0.83 and a 200-day moving average of $1.06. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $6.26. The company has a market cap of $147.79 million, a PE ratio of -1.14 and a beta of 2.16.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.08. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.50 million. Sell-side analysts expect that Seres Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Seres Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Hudson Bay Capital Management LP increased its position in Seres Therapeutics by 127.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock worth $4,760,000 after purchasing an additional 1,119,800 shares during the period. Handelsbanken Fonder AB raised its stake in shares of Seres Therapeutics by 10.0% during the 4th quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock worth $1,540,000 after buying an additional 100,000 shares during the last quarter. Rafferty Asset Management LLC raised its position in shares of Seres Therapeutics by 21.1% during the 3rd quarter. Rafferty Asset Management LLC now owns 936,382 shares of the biotechnology company’s stock worth $2,229,000 after purchasing an additional 162,995 shares during the last quarter. Barclays PLC lifted its stake in Seres Therapeutics by 24.3% in the 3rd quarter. Barclays PLC now owns 461,209 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 90,304 shares in the last quarter. Finally, Pennant Investors LP acquired a new stake in Seres Therapeutics during the 4th quarter valued at $409,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.